Smartkarma AI Primers, Smartkarma

αSK Primers

Smartkarma AI Primers

Smartkarma

Smartkarma unites the fragmented investment industry, connecting institutional investors, independent research providers, and corporates within a single network.

Research Reinvented

Equity Bottom-Up

Akums Drugs and Pharmaceuticals / Equity Bottom-Up

Akums Drugs and Pharmaceuticals (0200361D IN)

<ul>
  <li>Akums is the largest Contract Development and Manufacturing Organization (CDMO) in India, responsible for manufacturing a significant portion of the drugs consumed in the country, positioning it as a critical player in the domestic pharmaceutical supply chain.</li>
  <li>The company is on a strong growth trajectory, driven by capacity expansion, a growing client base of over 1,500 companies, and significant international contracts, including a multi-year, €200 million European deal and a $25 million partnership in Zambia.</li>
  <li>While demonstrating robust top-line growth and leadership in the CDMO segment, the company has faced recent margin pressures and a decline in net profit, alongside a notable income tax demand, which are key areas for investor monitoring.</li>
</ul><p><em>This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.</em></p>


  Akums is the largest Contract Development and Manufacturing Organization (CDMO) in India, responsible for manufacturing a significant portion of the drugs consumed in the country, positioning it as a critical player in the domestic pharmaceutical supply chain.
  The company is on a strong growth trajectory, driven by capacity expansion, a growing client base of over 1,500 companies, and significant international contracts, including a multi-year, €200 million European deal and a $25 million partnership in Zambia.
  While demonstrating robust top-line growth and leadership in the CDMO segment, the company has faced recent margin pressures and a decline in net profit, alongside a notable income tax demand, which are key areas for investor monitoring.
This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.

Primer: Akums Drugs and Pharmaceuticals (0200361D IN) - Aug 2026

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Primer: Akums Drugs and Pharmaceuticals (0200361D IN) - Aug 2026

Akums is the largest Contract Development and Manufacturing Organization (CDMO) in India, responsible for manufacturing a significant portion of...

αSK Primers